A Phase 4 interventional study of bevacizumab [Avastin] and Oxaliplatin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 38 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-18.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 52nd largest by enrollment of the 224 interventional ones that give a count, is one of 10 that started in 2008, is one of 8 in phase 4, and was the 58th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Gilead Sciences · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Oncolytics Biotech · Sites in United States
Ages 18+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 150 · Phase 3 48 · Phase 4 8
First in 2000; this study’s year is marked. 10 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 224 interventional studies. Of the 144 that completed or were terminated, 50 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 230 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 7 under way, none of them phase 3. Of 99 finished, 52 (53%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 23rd largest by enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2008, is one of 8 in phase 4, and was the 23rd registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
14 of the studies testing bevacizumab in Colorectal Neoplasms that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06280495Phase 3Sun Yat-sen UniversityNeoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | 2026-12-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT07007728Peking University Cancer Hospital & InstituteIparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis | 2026-12-31 |
| NCT03401294University of SaskatchewanConversion From Unresectable To Resectable Metastatic Colorectal Cancer. | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 230 studies testing bevacizumab in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate the efficacy and safety of a first-line regimen of Avastin and XELOX (oxaliplatin + Xeloda) in patients with metastatic cancer of the colon or rectum. Patients will receive 21-day cycles of treatment, comprising Avastin 7.5mg/kg iv on day 1, oxaliplatin 130mg/m2 iv on day 1, and Xeloda 1000mg/m2 po twice daily on days 1-14, for a maximum of 6 months. Patients with stable disease or complete or partial response may continue on Avastin therapy. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: Oxaliplatin · Drug: Xeloda
7.5mg iv on day 1 of each 3 week cycle
130mg/m2 iv on day 1 of each 3 week cycle
1000mg/m2 po bid on days 1-14 of each 3 week cycle
Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented neither a relapse nor a new colorectal cancer had occurred. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Baseline and Day 1 of every cycle until disease progression or death up to 5 years
PFS: Time to Event
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented that neither a relapse nor a new colorectal cancer had occurred. Median PFS was estimated using the Kaplan-Meier method.
Time frame: Baseline and Day 1 of every cycle until disease progression or death up to 5 years
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment
The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
Percentage of Participants With a CR or PR Among Participants in the ITT Population
CR and PR were defined using RECIST v1.0. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
Time to CR or PR Overall Response - Time to Event
Time to overall response (CR or PR) was calculated as the time between the date of start of treatment until first documented response (CR or PR defined per RECIST v1.0). Participants who did not achieve CR or PR were censored at the date of progression, death, or at last adequate tumor assessment date. Median time to CR or PR overall response was estimated using the Kaplan-Meier method.
Time frame: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
Percentage of Participants With a Best Overall Response of CR or PR During First Line Treatment
CR and PR were defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Duration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event
For participants with a best overall response of CR or PR, the duration of overall response was measured from the time that the criteria for CR or PR (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of overall response was estimated using the Kaplan-Meier method.
Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Percentage of Participants With a Stable Response During First Line Treatment
Stable response defined as participants with a best overall response of CR, PR, or stable disease (SD), defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started.
Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Duration of Stable Response
For participants with a best overall response of CR, PR, or SD during first line treatment, the duration of stable response was measured from the time that the criteria for CR, PR, or SD (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of stable response was estimated using the Kaplan-Meier method.
Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Percentage of Participants With Treatment Failure
Treatment-failure was defined as discontinuation of treatment for any reason, including the following qualifying events: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent).
Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Time to Treatment Failure
Time to treatment-failure was defined as the time from the first day of treatment to discontinuation of treatment for any reason, including: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). For participants who did not experience a qualifying event, their data were censored at the earlier of either the date of last tumour assessment or the date of the last intake of study medication. Median time to treatment-failure was estimated using the Kaplan-Meier method.
Time frame: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
Overall Survival: Percentage of Participants That Died Due to Any Cause
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive.
Time frame: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
Overall Survival: Time to Event
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. Median overall survival was estimated using the Kaplan-Meier method.
Time frame: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
Percentage of Participants Undergoing Surgical Intervention With Residual Disease Status Post-surgery
The percentage of participants who underwent surgery during the study period with an evaluation of their disease status after surgery. The surgery during the study period was described by reason: curative, palliative, biopsy, other, or unknown. Residual disease status after surgery was described as: no residual disease due to radical surgery, presence of residual disease, unknown or not applicable.
Time frame: At surgery, at least 6 to 8 weeks after last dose of bevacizumab up to 5 years
Percentage of Participants With Best Overall Response of CR or PR by Kirsten Rat Sarcoma Viral Oncogene Homolog (K-Ras)/V-Raf Murine Sarcoma Viral Oncogene Homolog B (B-Raf) Mutation Status
The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. The K-Ras and/or the B-Raf gene mutation status of participants was evaluated by the central laboratory using tumor samples. Wild-type participants did not have a mutation in either gene.
Time frame: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score
Quality of life (QoL) assessments were used to derive pre-specified QoL scores according to the QoL manual "EQ-5D-3 Level (3L)" user guide for instrument version 4.0. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The visual analog scale (VAS) component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The overall health score absolute changes were calculated for each participant as follows: (score at the end of treatment minus score at baseline). EQ-5D health states were converted into EQ-5D-3L raw index value by applying the scoring algorithm based on the European EQ-net VAS set. The raw index was chosen instead of rescaled index, since the questionnaire was used in order to obtain a quality of life assessment. The raw index scores ranged from 0 (worst health state) to 100 (best health state).
Time frame: Baseline, every 9 weeks (every 3 cycles), at end-of-treatment up to 5 years
| Milestone | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Started | 205 |
| Completed | 0 |
| Not completed | 205 |
| Withdrew: Adverse event | 52 |
| Withdrew: Progression of disease | 93 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Participant withdrew consent | 13 |
| Withdrew: Participant non-compliance | 5 |
| Withdrew: Need for surgery | 17 |
| Withdrew: Medical decision | 14 |
| Withdrew: Death | 6 |
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented neither a relapse nor a new colorectal cancer had occurred. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death | 50.25 |
The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment | 58.79 |
CR and PR were defined using RECIST v1.0. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Percentage of Participants With a CR or PR Among Participants in the ITT Population | 49.24 |
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented that neither a relapse nor a new colorectal cancer had occurred. Median PFS was estimated using the Kaplan-Meier method.
| months | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| PFS: Time to Event | 9.70 (8.43 to 10.49) |
Time to overall response (CR or PR) was calculated as the time between the date of start of treatment until first documented response (CR or PR defined per RECIST v1.0). Participants who did not achieve CR or PR were censored at the date of progression, death, or at last adequate tumor assessment date. Median time to CR or PR overall response was estimated using the Kaplan-Meier method.
| months | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Time to CR or PR Overall Response - Time to Event | 3.93 (2.56 to 4.66) |
CR and PR were defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Percentage of Participants With a Best Overall Response of CR or PR During First Line Treatment | 54.64 |
For participants with a best overall response of CR or PR, the duration of overall response was measured from the time that the criteria for CR or PR (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of overall response was estimated using the Kaplan-Meier method.
| months | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Duration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event | 8.52 (7.28 to 10.33) |
Stable response defined as participants with a best overall response of CR, PR, or stable disease (SD), defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started.
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Percentage of Participants With a Stable Response During First Line Treatment | 52.63 |
For participants with a best overall response of CR, PR, or SD during first line treatment, the duration of stable response was measured from the time that the criteria for CR, PR, or SD (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of stable response was estimated using the Kaplan-Meier method.
| months | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Duration of Stable Response | 10.39 (9.02 to 11.44) |
Treatment-failure was defined as discontinuation of treatment for any reason, including the following qualifying events: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent).
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Percentage of Participants With Treatment Failure | 82.74 |
Time to treatment-failure was defined as the time from the first day of treatment to discontinuation of treatment for any reason, including: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). For participants who did not experience a qualifying event, their data were censored at the earlier of either the date of last tumour assessment or the date of the last intake of study medication. Median time to treatment-failure was estimated using the Kaplan-Meier method.
| months | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Time to Treatment Failure | 6.69 (5.97 to 7.74) |
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive.
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Overall Survival: Percentage of Participants That Died Due to Any Cause | 50.76 |
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. Median overall survival was estimated using the Kaplan-Meier method.
| months | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Overall Survival: Time to Event | 23.15 (20.07 to 27.15) |
The percentage of participants who underwent surgery during the study period with an evaluation of their disease status after surgery. The surgery during the study period was described by reason: curative, palliative, biopsy, other, or unknown. Residual disease status after surgery was described as: no residual disease due to radical surgery, presence of residual disease, unknown or not applicable.
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Curative, no residual disease | 55.77 |
| Curative, residual disease | 13.46 |
| Curative, unknown | 3.85 |
| Curative, not applicable | 7.69 |
| Palliative, no residual disease | 3.85 |
| Palliative, residual disease | 7.69 |
| Palliative, unknown | 3.85 |
| Palliative, not applicable | 1.92 |
| Biopsy, residual disease | 1.92 |
| Biopsy, not applicable | 1.92 |
| Unknown, unknown | 1.92 |
| Unknown, not applicable | 3.85 |
| Other, residual disease | 1.92 |
| Other, not applicable | 3.85 |
The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis \<10 mm). No new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. The K-Ras and/or the B-Raf gene mutation status of participants was evaluated by the central laboratory using tumor samples. Wild-type participants did not have a mutation in either gene.
| percentage of participants | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Wild-type (n=18) | 88.89 |
| Gene mutation (n=15) | 66.67 |
Quality of life (QoL) assessments were used to derive pre-specified QoL scores according to the QoL manual "EQ-5D-3 Level (3L)" user guide for instrument version 4.0. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The visual analog scale (VAS) component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The overall health score absolute changes were calculated for each participant as follows: (score at the end of treatment minus score at baseline). EQ-5D health states were converted into EQ-5D-3L raw index value by applying the scoring algorithm based on the European EQ-net VAS set. The raw index was chosen instead of rescaled index, since the questionnaire was used in order to obtain a quality of life assessment. The raw index scores ranged from 0 (worst health state) to 100 (best health state).
| units on a scale | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Baseline | 80.24 ± 14.32 |
| Last visit | 74.94 ± 19.08 |
| Absolute change from baseline | -5.30 ± 19.13 |
Collected over Adverse events (AE) were collected from the date of first administration of study treatment until 28 days after the last dose of study treatment up to 5 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab | — | 56/197 (28.4%) | 179/197 (90.9%) |
| Event | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/197 |
| DiarrhoeaGastrointestinal disorders | 4/197 |
| SubileusGastrointestinal disorders | 4/197 |
| HypersensitivityImmune system disorders | 3/197 |
| PneumoniaInfections and infestations | 3/197 |
| Hypertensive crisisVascular disorders | 3/197 |
| Intestinal obstructionGastrointestinal disorders | 2/197 |
| Intestinal perforationGastrointestinal disorders | 2/197 |
| AstheniaGeneral disorders | 2/197 |
| CachexiaMetabolism and nutrition disorders | 2/197 |
| Event | Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| NauseaGastrointestinal disorders | 84/197 |
| DiarrhoeaGastrointestinal disorders | 73/197 |
| AstheniaGeneral disorders | 60/197 |
| ParaesthesiaNervous system disorders | 59/197 |
| VomitingGastrointestinal disorders | 48/197 |
| HypertensionVascular disorders | 45/197 |
| PyrexiaGeneral disorders | 40/197 |
| Neuropathy peripheralNervous system disorders | 38/197 |
| NeutropeniaBlood and lymphatic system disorders | 32/197 |
| Abdominal painGastrointestinal disorders | 29/197 |
Safety population: all enrolled participants who received at least 1 dose of all study medications.
| Age, Continuous(years) | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Mean | 62.25 ± 9.94 |
| Sex: Female, Male(Participants) | Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab |
|---|---|
| Female | 86 |
| Male | 111 |
The record gives a start of Feb 2008, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Oxaliplatin · Capecitabine